Propranolol: What is BLOCKing its clinical investigation in breast cancer?

Anne H. Blaes; Evidio Domingo-Musibay; Kevin Kalinsky

doi:10.1158/1078-0432.CCR-19-3818

Propranolol: What is BLOCKing its clinical investigation in breast cancer?

Anne H. Blaes, Evidio Domingo-Musibay, Kevin Kalinsky

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis. See related article by Hiller et al., p. 1803.

Original language	English (US)
Pages (from-to)	1781-1783
Number of pages	3
Journal	Clinical Cancer Research
Volume	26
Issue number	8
DOIs	https://doi.org/10.1158/1078-0432.CCR-19-3818
State	Published - Apr 15 2020

Bibliographical note

Publisher Copyright:
© 2020 American Association for Cancer Research.

Keywords

Biomarkers
Breast Neoplasms
Cell Line, Tumor
Cell Proliferation
Epithelial-Mesenchymal Transition
Humans
Propranolol
Tumor Microenvironment

PubMed: MeSH publication types

Comment
Research Support, Non-U.S. Gov't
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1158/1078-0432.CCR-19-3818

Find It

Find It at U of M Libraries

Cite this

@article{b5fb05f5b8d44b148d2705d504199fff,

title = "Propranolol: What is BLOCKing its clinical investigation in breast cancer?",

abstract = "Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis. See related article by Hiller et al., p. 1803. ",

keywords = "Biomarkers, Breast Neoplasms, Cell Line, Tumor, Cell Proliferation, Epithelial-Mesenchymal Transition, Humans, Propranolol, Tumor Microenvironment",

author = "Blaes, {Anne H.} and Evidio Domingo-Musibay and Kevin Kalinsky",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2020",

month = apr,

day = "15",

doi = "10.1158/1078-0432.CCR-19-3818",

language = "English (US)",

volume = "26",

pages = "1781--1783",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "8",

}

TY - JOUR

T1 - Propranolol

T2 - What is BLOCKing its clinical investigation in breast cancer?

AU - Blaes, Anne H.

AU - Domingo-Musibay, Evidio

AU - Kalinsky, Kevin

PY - 2020/4/15

Y1 - 2020/4/15

N2 - Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis. See related article by Hiller et al., p. 1803.

AB - Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis. See related article by Hiller et al., p. 1803.

KW - Biomarkers

KW - Breast Neoplasms

KW - Cell Line, Tumor

KW - Cell Proliferation

KW - Epithelial-Mesenchymal Transition

KW - Humans

KW - Propranolol

KW - Tumor Microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85083487794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083487794&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-3818

DO - 10.1158/1078-0432.CCR-19-3818

M3 - Article

C2 - 32029438

AN - SCOPUS:85083487794

SN - 1078-0432

VL - 26

SP - 1781

EP - 1783

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 8

ER -

Propranolol: What is BLOCKing its clinical investigation in breast cancer?

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this